| BEP | brain evoked potential; basic element of performance |
|---|---|
| CE | California encephalitis; cardiac enlargement; cardioesophageal; carotid endarterectomy; catamenial e... |
| CRE | cumulative radiation effect; cyclic adenosine monophosphate-response element |
| CREM | center for rural emergency medicine; cyclic adenosine monophosphate-response element modulator |
| 3DFEM | three-dimensional finite element method |
| noble element | A metal that cannot be oxidised by heat alone, nor readily dissolved by acid; e.g., gold, platinum. Synonym: noble element. (05 Mar 2000) |
|---|---|
| dyad symmetry element | Dyad symmetry element bound by serum response factor to control the expression of c fos. (18 Nov 1997) |
| Is element | Mobile nucleotide sequences that occur naturally in the genomes of bacterial populations. When inserted into bacterial DNA, they inactivate the gene concerned, when they are removed the gene regains its activity. Closely related to transposons and range in size from a few hundred to a few thousand bases, but are usually less than 1500 bases. (18 Nov 1997) |
| electronegative element | An element whose atoms have a tendency to accept electrons and form negative ions (e.g., oxygen, sulfur, chlorine, etc.). (05 Mar 2000) |
| electropositive element | <chemistry> An element whose atoms have a tendency to lose electrons and form positive ions (e.g., sodium). (05 Mar 2000) |
| element | <chemistry> One of the 103 known chemical substances that cannot be divided into simpler substances by chemical means. A substance whose atoms all have the same atomic number. Examples: hydrogen, lead, uranium.(See atom, matter, nuclide.) (16 Dec 1997) |
| trace element | Any chemical element that an organism needs very small quantities of tosurvive. (09 Oct 1997) |
| transitional element | <cell biology> Region at the boundary of the rough endoplasmic reticulum and the Golgi. Transport vesicles are responsible for the transfer of secretory proteins from this part of the rough endoplasmic reticulum to the Golgi system. (18 Nov 1997) |
| enhancer element | <molecular biology> A DNA sequence, present in the genomes of higher eukaryotes and of various animal viruses, which can increase the transcription of genes into messenger RNA. These control element frequently found 5' to the start site of a gene, when bound by a specific transcription factor, enhance the levels of expression of the gene, but are not sufficient alone to cause expression. Distinguished from a promoter, that is alone sufficient to cause expression of the gene when bound, in practice, the two terms merge. Enhancers usually can function in either orientation and at various distances from a promoter. Compare: promoter. (03 Jul 1999) |
| transposable element | <molecular biology> Small, mobile DNA sequences that can replicate and insert copies at random sites within chromosomes. They have nearly identical sequences at each end, oppositely oriented (inverted) repeats and code for the enzyme, transposase, that catalyses their insertion. Bacteria have two types of transposon, simple transposons that have only the genes needed for insertion and complex transposons that contain genes in addition to those needed for insertion. Eukaryotes contain two classes of mobile genetic elements, the first are like bacterial transposons in that DNA sequences move directly. The second class (retrotransposons) move by producing RNA that is transcribed, by reverse transcriptase, into DNA which is then inserted at a new site. (13 Nov 1997) |
| extrachromosomal element | Any heritable element not associated with the chromosome. It is usually a plasmid or the DNA of organelles such as mitochondria and chloroplasts. (18 Nov 1997) |
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
| amino acid receptor | <biochemistry> Ligand gated ion channels with specific receptors for amino acid transmitters. An extended protein superfamily that also includes subunits of the nicotinic acetylcholine receptor. (18 Nov 1997) |
| AMPA receptor | <cell biology> Glutamate operated ion channel. See: excitatory amino acid receptor channels. (05 Feb 1998) |
| ANP receptor | <molecular biology> Family of 3 receptors for atrial natriuretic peptide. ANP A and ANP B have intracellular guanylate cyclase and protein kinase like domains. ANP C, shares the extracellular ligand binding and transmembrane domains, but lacks the functional intracellular domains and is not thought to be involved in signal transduction. (18 Nov 1997) |